AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Metastatic Hormone Refractory Prostate Cancer Pipeline Insight, 2019 - Complete Product Development Cycle Report - ResearchAndMarkets.com

April 9, 2019

DUBLIN--(BUSINESS WIRE)--Apr 9, 2019--The “Metastatic Hormone Refractory Prostate Cancer - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

The report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Metastatic Hormone Refractory Prostate Cancer development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

The report assesses the active Metastatic Hormone Refractory Prostate Cancer pipeline products by developmental stage, product type, molecule type, and administration route.

Scope of the report

  • The report provides a snapshot of the pipeline development for the Metastatic Hormone Refractory Prostate Cancer
  • The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Metastatic Hormone Refractory Prostate Cancer
  • The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Metastatic Hormone Refractory Prostate Cancer
  • The report also covers the dormant and discontinued pipeline projects related to the Metastatic Hormone Refractory Prostate Cancer

Key Topics Covered:

1. Report Introduction

2. Metastatic Hormone Refractory Prostate Cancer Overview

3. Pipeline Therapeutics

  • An Overview of Pipeline Products for Metastatic Hormone Refractory Prostate Cancer

4. Comparative Analysis

5. Products in Clinical Stage

  • Product Description
  • Research and Development
  • Product Development Activities

6. Products in Pre-Clinical and Discovery Stage

  • Product Description
  • Research and Development
  • Product Development Activities

7. Therapeutic Assessment

  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

8. Inactive Products

  • Product Description
  • Research and Development
  • Product Development Activities

Companies Mentioned

  • AB Science SA
  • AbbVie Inc.
  • Adamis Pharmaceuticals Corporation
  • Advaxis
  • Ambrx
  • Amgen Inc
  • Armour Therapeutics Inc.
  • ArQule
  • Arrowhead Pharmaceuticals
  • AstraZeneca Plc
  • Astellas
  • ATLAB Pharma SAS
  • Bavarian Nordic A/S
  • BIND Therapeutics

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/tp28e3

View source version on businesswire.com:https://www.businesswire.com/news/home/20190409005644/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Prostate Cancer Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 04/09/2019 09:15 AM/DISC: 04/09/2019 09:15 AM

http://www.businesswire.com/news/home/20190409005644/en